Long-term antitumour effects of pasireotide in acromegaly
Authors' conclusion
Pasireotide appears to induce durable cystic degeneration in somatotroph tumours, with evidence suggesting sustained antitumor effects that may extend beyond treatment discontinuation. These findings support its potential for a broader therapeutic role, warranting validation in future prospective studies.
Study context
- Population
- Patients with acromegaly from the previously published PAPE study; 57% male; median age 52 years (IQR 15)
- Participants
- 44 patients
- Outcome
- Long-term antitumour effects: T2-intensity ratio (grey matter reference) and tumour volume on magnetic resonance imaging (MRI)
- Follow-up
- 8 years
Main finding
As reported in the abstract
Median T2-IR, baseline to 8 years (P < .001); progressive cystic degeneration
1.03 to 1.56
Median tumour volume, baseline to 8 years (P = .005)
1239 to 603 mm³
Observational data: associations, not effects.
Further findings
Reduction in medical acromegaly treatment, without surgery or radiotherapy, due to decreasing IGF-1
- Patients with reduced medical acromegaly treatment
- 12 (27.3%)
Duration of pasireotide treatment
- Median duration of pasireotide treatment
- 31.0 months
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →